This predictive-prognostic paradox could be reconciled if Ki-67 expression modulated a CSC-drug resistant population, and therapeutic effectiveness was evaluated not by gross response of tumor shrinkage, but by assessing Ki-67 expression in remaining tumor tissue post chemotherapy. This evidence concerns the gene MKI67 and neoplasm.